文献速递临床试验与 GCP基础与转化研究

一项开放标签随机对照试验评估生酮饮食在脓毒症危重患者中的应用

An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis.
PubMed 文献 · Sci Transl Med · 2024-07-10

该单中心、开放标签随机对照试验将40例脓毒症危重成人随机分配至生酮饮食组或标准高碳水饮食组,评估生酮饮食能否诱导稳定酮症。结果显示生酮饮食组全部患者达到稳定酮症,β-羟丁酸水平较对照组显著升高,未观察到重大不良事件或有害代谢副作用,且生酮组无通气、无升压药、无透析和ICU外天数更高,但30天生存率无差异;作者认为需更大规模试验进一步研究生酮饮食对脓毒症相关器官功能障碍的潜在获益。

要点

  • 生酮饮食组全部患者达到稳定酮症,β-羟丁酸平均差异1.4毫摩尔/升(95%CI 1.0至1.8,P<0.001)。
  • 未观察到重大不良事件或酸中毒、血糖异常、血脂异常等有害代谢副作用。
  • 第4天后生酮组无需胰岛素治疗,对照组胰岛素依赖比例为35%至60%(P=0.009)。

核心结论

  • 该试验表明在脓毒症中可安全诱导稳定生酮状态,需更大规模试验研究其对脓毒症相关器官功能障碍的潜在获益。

研究设计与样本

  • 单中心、开放标签、随机对照试验,纳入40例脓毒症危重成人,随机分配至生酮饮食组或标准高碳水化合物饮食组。

主要发现

  • 生酮饮食组全部患者达到稳定酮症,β-羟丁酸水平较对照组平均差异1.4毫摩尔/升(95%CI 1.0至1.8,P<0.001)。
  • 未观察到重大不良事件或有害代谢副作用(酸中毒、血糖异常或血脂异常)。
  • 第4天后生酮饮食组无患者需要胰岛素治疗,而对照组胰岛素依赖比例为35%至60%(P=0.009)。
  • 30天生存率无差异;生酮组无通气天数(IRR 1.7;95%CI 1.5至2.1;P<0.001)、无升压药天数(IRR 1.7;95%CI 1.5至2.0;P<0.001)、无透析天数(IRR 1.5;95%CI 1.3至1.8;P<0.001)和ICU外天数(IRR 1.7;95%CI 1.4至2.1;P<0.001)更高。
  • CD4+/CD8+ T细胞二代测序和蛋白分析显示免疫失调减少,T细胞活化和信号标记基因表达降低,促炎细胞因子分泌减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with sepsis experience metabolic and immunologic dysfunction that may be amplified by standard carbohydrate-based nutrition. A ketogenic diet (KD) may offer an immunologically advantageous alternative, although clinical evidence is limited. We conducted a single-center, open-label, randomized controlled trial to assess whether a KD could induce stable ketosis in critically ill patients with sepsis. Secondary outcomes included assessment of feasibility and safety of KD, as well as explorative analysis of clinical and immunological characteristics. Forty critically ill adults were randomized to either a ketogenic or standard high-carbohydrate diet. Stable ketosis was achieved in all KD patients, with significant increases in β-hydroxybutyrate levels compared with controls [mean difference 1.4 milimoles per liter; 95% confidence interval (CI): 1.0 to 1.8; P < 0.001). No major adverse events or harmful metabolic side effects (acidosis, dysglycemia, or dyslipidemia) were observed. After day 4, none of the patients in the KD group required insulin treatment, whereas in the control group, insulin dependency ranged between 35% and 60% (P = 0.009). There were no differences in 30-day survival, but ventilation-free [incidence rate ratio (IRR) 1.7; 95% CI: 1.5 to 2.1; P < 0.001], vasopressor-free (IRR 1.7; 95% CI: 1.5 to 2.0; P < 0.001), dialysis-free (IRR 1.5; 95% CI: 1.3 to 1.8; P < 0.001), and intensive care unit-free days (IRR 1.7; 95% CI: 1.4 to 2.1; P < 0.001) were higher in the ketogenic group. Next-generation sequencing of CD4+/CD8+ T cells and protein analyses showed reduced immune dysregulation, with decreased gene expression of T-cell activation and signaling markers and lower pro-inflammatory cytokine secretion. This trial demonstrated the safe induction of a stable ketogenic state in sepsis, warranting larger trials to investigate potential benefits in sepsis-related organ dysfunction.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Rahmel T, Effinger D, Bracht T, et al. An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis. Sci Transl Med. 2024. PMID: 38985853. doi:10.1126/scitranslmed.adn9285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。